GO
Loading...

Sanofi SA

More

  • *Developed by UniQure and marketed in Europe by Chiesi. FRANKFURT/ LONDON, Nov 26- The Western world's first gene therapy drug is set to go on sale in Germany with a 1.1 million euro price tag, a new record for a medicine to treat a rare disease. The sky-high cost of Glybera, from Dutch biotech firm UniQure and its unlisted Italian marketing partner Chiesi, shows how...

  • Nov 20- Global pharmaceutical spending will break the trillion dollar mark in 2014, driven by high prices in the United States for novel treatments such as Gilead Sciences Inc's Sovaldi for hepatitis C and new cancer drugs, according to a study released on Thursday. Total spending on drugs will hit $1.06 trillion, an increase of 7 percent over 2013 levels,...

  • CHICAGO, Nov 17- Regeneron Corp's experimental drug alirocumab helped 10 times as many high-risk patients unable to tolerate widely-used statins get their "bad" LDL cholesterol down to target levels than Merck& Co's Zetia, according to data from a clinical trial presented on Monday. Alirocumab, developed along with French drugmaker Sanofi, belongs to a new...

  • *GlaxoSmithKline again leads index for best drug access. The contradictory advances and the problems facing the industry are evident at GlaxoSmithKline, which retained its long-standing top spot in the index, while simultaneously featuring in a major bribery scandal in China. "Corruption is terrible, but it also takes attention away from the fact that these...

  • FDA approves Lemtrada for multiple sclerosis Saturday, 15 Nov 2014 | 1:00 PM ET

    NEW YORK— The Food and Drug Administration has approved Lemtrada, a treatment for relapsing multiple sclerosis made by the drugmaker Genzyme. Sanofi, the parent company of Genzyme, wants to market Lemtrada as a treatment for relapsing multiple sclerosis, a disease in which the immune system attacks healthy nerves. Sanofi estimates that the disease affects...

  • LONDON, Nov 13- AstraZeneca is developing an antibody treatment to reverse the blood-thinning effect of its heart drug Brilinta in rare emergency situations, such as urgent surgery or in the event of major bleeding. AstraZeneca said on Thursday the experimental antibody product, MEDI2452, was in pre-clinical tests at its MedImmune biotech unit.

  • LONDON, Nov 6- Recent U.S. tax changes have weakened the case for companies like Pfizer to shift their tax bases overseas by striking so-called tax inversion deals, according to AstraZeneca's chief executive. AstraZeneca fended off a $118 billion takeover bid from its larger U.S. rival in May but there is speculation Pfizer may return after Nov. 26, when it is...

  • In September life-science company Calico, which was set up by Google last year to investigate the ageing process, joined with U.S. drugmaker AbbVie in committing an initial $250 million apiece to developing cures for age-related diseases. Away from the limelight, however, Switzerland's Novartis and Denmark's Novo Nordisk are already testing new roles for...

  • Nov 4- Regeneron Pharmaceuticals Inc cut the top end of its full-year sales forecast for its blockbuster eye drug and reported a lower-than-expected adjusted quarterly profit, citing higher costs. Regeneron's net profit fell to $79.7 million, or 70 cents per share, in the third quarter ended Sept. 30 from $141.3 million, or $1.25 per share, a year earlier.

  • Nov 4- Regeneron Pharmaceuticals Inc reported a higher quarterly revenue on increased sales of its eye injection Eylea. The biotechnology company's net profit fell to $79.7 million, or 70 cents per share, in the third quarter Sept. 30, from $141.3 million, or $1.25 per share, a year earlier. Revenue rose 21.6 percent to $725.8 million and included collaboration...

  • INSIGHT-How the wheels came off for Sanofi's CEO Sunday, 2 Nov 2014 | 4:31 AM ET

    PARIS/ LONDON, Nov 2- Chris Viehbacher speaks plainly. "We had somewhat of a mess in Brazil," he told financial analysts in August 2013, "so that's why I decided to change management." Fifteen months later he has gone the same way as the Brazilian employees he sacked so decisively- fired as chief executive of French drugmaker Sanofi at a dawn board meeting, with the "mess in...

  • Although Paris- listed, the firm has less than a quarter of its employees in France, while a majority of its shareholders are to be found outside the country. However, comments from the ex-CEO himself and sources close to the board made clear that his decision to move to Boston from Paris in June, and to consider cutting jobs in France without sharing the ideas at the...

  • Europe closes mixed as Fed eyed; Sanofi tumbles Wednesday, 29 Oct 2014 | 12:50 PM ET

    European shares closed marginally higher on Wednesday, after a bumpy day of trading, as investors looked ahead to the Fed's policy statement.

  • UPDATE 6-French drugmaker Sanofi sacks CEO, shares drop Wednesday, 29 Oct 2014 | 12:36 PM ET

    *Sanofi board says not changing company's strategy. PARIS, Oct 29- Sanofi's board ousted its chief executive of six years on Wednesday, criticising him for an authoritarian management style that was often popular with investors as he lifted the French drugmaker onto the global stage. Sanofi said it would continue the international expansion pursued under...

  • Sanofi's sacking of CEO is 'shocking'     Wednesday, 29 Oct 2014 | 12:05 PM ET

    Editor of SCRIP Intelligence, Eleanor Malone, says it's a "shocking move" for Sanofi to sack its CEO over what she described as "relatively small misdemeanours."

  • Sanofi fires CEO     Wednesday, 29 Oct 2014 | 10:16 AM ET

    Insight to why Sanofi's CEO Chris Viehbacher could have been ousted at the company, with CNBC's Meg Tirrell.

  • Boehringer and Lilly will continue to jointly develop and market these drugs in 17 countries, including the United States, they said in a statement on Wednesday. A new insulin glargine product, which is approved in Europe, has won tentative approval in the United States. Sanofi SA said on Tuesday that growth in sales of its diabetes drugs would stall next year due...

  • Sanofi CEO ousted by board     Wednesday, 29 Oct 2014 | 9:17 AM ET

    CNBC's David Faber reports Sanofi CEO Christopher Viehbacher has been fired by the French drug maker's board of directors.

  • UPDATE 1-Behind the scenes of Sanofi's boardroom bust up Wednesday, 29 Oct 2014 | 8:25 AM ET

    PARIS, Oct 29- A boardroom tussle brewing for months at Sanofi came to a head on Wednesday when France's top drugmaker fired its chief executive, wiping more billions off its share price. While the showdown played out in leaks to national newspapers has stunned investors as a "how not to do it" guide to corporate governance, the writing was on the wall in the...

  • Early Movers: HSY, FB, GRMN, WLP, EA, DAL & more Wednesday, 29 Oct 2014 | 8:16 AM ET
    A trader works on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.